We are in the initial clinical development stage with our product candidates in muscle health and blood. We have completed a Clinical Study for AXA2678 in healthy individuals, which yielded data that we believe supports this product candidate’s potential atrophy-mitigating effects during limb immobilization. We are currently conducting an initial Clinical Study of AXA4010, a product candidate with the potential to support blood health.
|Product Candidate||Area of Focus||Potential Indication||Initial Clinical Studies1||Therapeutic Development2|
Planned cohort 1 readout: Q4 2020
N=24, 3 cohorts, 1 dose
|AXA2678||Muscle||Limb immobilization- induced acute atrophy||
N=20, 2 arms, 1 dose
- Initial Clinical Studies refers to non-IND Clinical Studies initiated prior to a development path decision.